Company profile for ATAI Life Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders. We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. By pooling expertise, best practices, and resources across our ent...
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders. We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Barer Straße 7 80333 München
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/05/3181304/0/en/atai-Life-Sciences-and-Beckley-Psytech-Announce-the-Successful-Completion-of-Their-Strategic-Combination-to-Create-AtaiBeckley-a-Global-Leader-in-Transformative-Mental-Health-Thera.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/20/3169848/0/en/atai-Life-Sciences-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Common-Shares.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3168328/0/en/atai-Life-Sciences-and-Beckley-Psytech-Announce-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-BPL-003-Underscoring-its-Potential-in-Treatment-Resistant-Depression.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3168331/0/en/atai-Life-Sciences-Announces-Proposed-Public-Offering-of-Common-Shares.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/09/23/3154533/0/en/atai-Life-Sciences-and-Beckley-Psytech-Report-Positive-Phase-2a-Data-Demonstrating-Improved-Outcomes-with-a-Two-Dose-Induction-Regimen-of-BPL-003-in-Patients-with-Treatment-Resista.html

GLOBENEWSWIRE
23 Sep 2025
Atai Life Sciences Secures NIH Grant
Atai Life Sciences Secures NIH Grant

18 Sep 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/09/18/3152334/0/en/atai-Life-Sciences-Awarded-Grant-from-the-National-Institutes-of-Health.html

GLOBENEWSWIRE
18 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty